On Tuesday 3 November the Therapeutic Goods Administration registered Wegovy tablets for use in Australia. It is the first GLP-1 receptor agonist approved here in oral form, and it is the moment the Australian market stops being a two-tier arrangement where the only options are weekly injections.
The approval itself is straightforward. The interesting part is everything around it: how oral semaglutide even works, why the tablet is dosed thirty times higher than the injection, and what it does and does not fix about access.
What was approved
The TGA granted registration for four tablet strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. The indications are the same as the injectable form, chronic weight management as an adjunct to a reduced-energy diet and increased physical activity, and reduction of major adverse cardiovascular events in eligible adults.
For anyone who wants to check the primary documents rather than a news summary, the ARTG entries are 522753, 522757, 522758 and 522759.
Eligibility follows the label rather than the hype. Adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related comorbidity, are in scope. As Brisbane obesity physician Dr Brendan Hanrahan pointed out to the Guardian, that comorbidity list is broad, from knee osteoarthritis to fatty liver, and he questions the BMI cutoffs themselves given waist circumference is a better predictor of risk. Men above 94 cm and women above 80 cm are the usual thresholds.
Novo Nordisk has said it is working towards availability later this year, with the Guardian reporting the tablets are expected on shelves before Christmas. No Australian price has been announced.
Why the tablet dose looks insane
A 25 mg semaglutide tablet is roughly equivalent to a 2.4 mg injection. That is not a typo, and it is the single most useful thing to understand about this approval.
Semaglutide is a peptide. Peptides are digested. The gut is extremely good at destroying them before they reach the bloodstream, which is why injectable peptides work at microgram and milligram doses while the same molecule swallowed needs an order of magnitude more to achieve the same plasma exposure. Oral semaglutide gets around this with a co-formulation using sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, SNAC for short, which raises local gastric pH and helps the peptide cross the gastric mucosa intact.
The cost of that trick is a very narrow absorption window, and the narrow window dictates the administration rules everyone complains about. One tablet on an empty stomach with no more than a sip of water, on waking, then nothing to eat, drink or take orally for 30 minutes. Coffee counts. Other tablets count. Get it wrong and you have effectively taken nothing, which is a far more likely explanation for a stalled week than a sudden tolerance.
Dose escalation follows the injectable pattern, starting low and stepping up over about 16 weeks unless side effects intervene.
The Australian market angle
Novo has flagged Australia as a priority market, and the US numbers explain why. In the United States the pill launched on 5 January this year and passed three million prescriptions in just over five months, which Novo described as one of the strongest launches by volume on record. Roughly one script every five seconds. Most of those prescriptions, per the company, went to people new to GLP-1 therapy rather than switchers, which is the interesting bit: oral formulations appear to pull in people who would not inject.
The RACGP has welcomed it. President Dr Michael Wright called it a step forward, noting that the need for injection has been one of the main limits on uptake.
But registration is not subsidy. The PBS still subsidises weight-loss drugs only for people with type 2 diabetes. The injectable Wegovy was recommended for PBS listing by the PBAC almost a year ago and still has not been listed. There is no reason to expect the tablet to move faster. So the pill will be private script, full price, at a number nobody has published.
That matters commercially in a way that is easy to miss. A daily tablet with no refrigeration and no sharps is more convenient, but convenience was never the barrier for most Australians. Cost is. If the private price lands near the injection, this changes adherence and reach in the margins. If it lands cheaper, the effect on grey-market demand could be substantial, because the main reason people buy unapproved peptides online is that the approved product is out of reach.
The bits worth being careful about
The TGA explicitly warned against combining formulations: no Wegovy tablets alongside Wegovy injections, and no pairing with any other GLP-1 receptor agonist. That sounds obvious until you look at how people actually behave. We have written before about stacking and about the survey data showing people combining compounds that were never studied together. Regulators write this line because it keeps happening.
Second, the approval covers registration of the drug, and packaging and manufacturing processes still need to clear their own steps, which is why availability is “later this year” rather than “now”.
Third, oral semaglutide is semaglutide. Nothing about the tablet changes the adverse event profile class-wide, including the eye signal that the FDA moved on this week and that we covered separately. Gastrointestinal effects remain the common complaint, and the fasting administration rule makes adherence failure a distinct risk that injections do not have.
Fourth, Eli Lilly’s oral orforglipron is still waiting on a TGA decision. When that lands, Australia will have two oral GLP-1 options on different mechanisms, one a peptide and one a small molecule, and the comparison will finally be about price and tolerability rather than novelty.
What the Research Says
- The TGA registered oral semaglutide (Wegovy tablets) on 3 November 2026 in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, indicated for chronic weight management and for reducing the risk of major adverse cardiovascular events in eligible adults, indications consistent with the injectable formulation. Source: RACGP newsGP, “TGA approves Wegovy weight-loss pill,” 4 November 2026; ARTG entries 522753, 522757, 522758, 522759.
- A 25 mg tablet is described as acting like a 2.4 mg injection because oral peptide absorption is inefficient; the tablet must be taken on an empty stomach with a sip of water, with a 30 minute wait before food, drink or other oral medication. Source: ABC News, “Daily weight-loss tablet Wegovy cleared for use in Australia,” 3 November 2026; RACGP newsGP, same date.
- Eligibility covers adults with BMI of 30 or above, or BMI 27 to 30 with at least one weight-related comorbidity, with dose escalation over 16 weeks. Source: The Guardian, “Australia’s first GLP-1 weight-loss pill has been approved,” 3 November 2026.
- In the United States the oral formulation launched 5 January 2026 and exceeded three million prescriptions in just over five months, with the majority going to patients new to GLP-1 therapy. Source: Novo Nordisk statement reported by RACGP newsGP, 4 November 2026.
- The TGA advised against concomitant use of Wegovy tablets or injection with any other semaglutide-containing product or any other GLP-1 receptor agonist. Source: TGA approval statement as reported by RACGP newsGP, 4 November 2026.
- PBS subsidy for weight-loss medicines currently applies only to people with type 2 diabetes, and the injectable Wegovy remains unlisted despite a PBAC recommendation made almost a year earlier. Source: ABC News, 3 November 2026; Guardian, 3 November 2026.
What it changes, and what it does not
It changes the shape of the legal market. A daily pill with no cold chain and no needles is a real option for people who were never going to inject, and the US launch data suggests that population is larger than the industry expected.
It does not change the economics. Without PBS listing, the people who most need it are still paying retail, and grey-market demand is driven almost entirely by price and access rather than by formulation preference.
It also does not change the evidence base. Everything we know about semaglutide comes from controlled dosing with known product. A tablet skipped because someone had a coffee first is not the same drug exposure as a 2.4 mg injection, and the community would do well to treat “the pill did not work for me” as a technique question before a pharmacology one.
We are watching for the Australian price announcement and the orforglipron decision in the Grey Highway Telegram group. Compound background is on the semaglutide page, and the oral small-molecule comparison sits on the tirzepatide page for context on how the injectable alternatives differ.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.